Senores Pharma to buy Apnar Pharma at enterprise value of Rs 91 crore

Ruchika Sharma

Senores Pharma to buy Apnar Pharma at enterprise value of Rs 91 crore

Written By : Ruchika Sharma Published On 2025-12-16T14:53:14+05:30 | Updated On 16 Dec 2025 2:53 PM IST

Ahmedabad: Senores Pharma has announced that the Company has entered into a Share Purchase Agreement for acquisition of 100 percent share capital of Apnar Pharma in two tranches.

Upon consummation of the acquisition, Apnar Pharma shall become a wholly owned subsidiary of the Company.

The acquisition of 100% equity shares in the Apnar Pharma at total enterprise value is Rs. 91 crores. Of this, Rs 76 crores comprises total debt plus excepted liabilities related to the Plant to be taken over by Senores. The remaining Rs 15 crores will be paid in cash in two tranches, with 75% payable in the first tranche and 25% in the second tranche.

1st Tranche of the Transaction to be completed in current fiscal by March 2026 and 2nd tranche is expected to complete by Q2 of FY 2027.

Apnar Pharma is a pharmaceutical company primarily engaged in the business of manufacture of generic pharmaceutical formulations, having US FDA, UK-MHRA and Health Canada approved manufacturing facility near Vadodara, Gujarat.

Senores Pharmaceuticals Limited is a global, research- driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The companies’ current portfolio includes 46 ANDAs and 133 strengths along with a pipeline of 22 ANDAs and 52 strengths In the CMO/CDMO vertical 8 ANDAs and 24 products permitted for distribution in the USA along with a pipeline of 16 ANDAs and 57 strengths. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets, catering to more than 40 countries.

The company currently has approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 394 product registrations and 824 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (“API”).

Senores has 2 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA, TAA & BAA compliant for controlled substances and government supplies & other is in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).

Read also: Senores Pharma gets Philippine FDA approval for basket of 10 products

senores pharmasenores pharma newsacquisitionapnar pharma

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751